Skip to main content
Premium Trial:

Request an Annual Quote

OncoCyte: Melinda Griffith

OncoCyte has appointed Melinda Griffith to its board of directors. Griffith is a senior executive who has led business development, licensing, and legal activities for a number of diagnostic, device and pharmaceutical companies. In addition to her board appointment for OncoCyte, she currently serves as vice president of strategic alliances and chief legal counsel for the Parker Institute for Cancer Immunotherapy an dis chair of the board of directors for intenrational health non-profit Thrive Networks.

Prior to this, Griffith held a number of executive roles at public and private biotech companies, including GE Healthcare's Clarient Cancer Laboratories, Genelabs Technologies, CardioDx, Tethys BioSciences, and Axys Pharmaceuticals, Cetus Corporation, and Hoffmann La-Roche.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.